Hikma has provided a reassuring Q1 21 business update – Injectables benefited from new launches while the momentum in Generics was driven by COVID-19-related products. While demand for such products could normalise, Generics should benefit from the ‘much-awaited’ launch of the Advair copycat in the coming quarters. Within Injectables, a pick-up in elective procedures in the US, as people get vaccinated, should be a key growth driver. Combined with the new licensing deals announced recently, we s ....
03 May 2021
Reassuring Q1 points to solid full year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Reassuring Q1 points to solid full year
Hikma Pharmaceuticals Plc (HIK:LON) | 1,820 18.2 0.1% | Mkt Cap: 4,038m
- Published:
03 May 2021 -
Author:
Amandeep Goyal -
Pages:
3
Hikma has provided a reassuring Q1 21 business update – Injectables benefited from new launches while the momentum in Generics was driven by COVID-19-related products. While demand for such products could normalise, Generics should benefit from the ‘much-awaited’ launch of the Advair copycat in the coming quarters. Within Injectables, a pick-up in elective procedures in the US, as people get vaccinated, should be a key growth driver. Combined with the new licensing deals announced recently, we s ....